Helicobacter pylori infection induces chronic inflammation of the gastric mucosa and thus profoundly affects gastric physiology. In the acute phase of infection, gastric acid secretion is transiently impaired. The morphological damage of the gastric mucosa, changes in gastric hormone release, and disruption of neural pathways all contribute to influence gastric acid secretion in a distinct manner. Changes in gastric acid secretion, whether impaired or increased, are intimately related with the topographic phenotypes of gastritis and the presence of atrophy or absence of corpus atrophy. The interplay of gastritis phenotype and acid secretion are key determinants in disease outcomes. Corpus-predominant gastritis and corpus atrophy are accompanied by hypochlorhydria and carry the highest risk for gastric cancer, whereas antrum-predominant gastritis with little involvement of the corpus-fundic mucosa is associated with hyperchlorhydria and predisposes to duodenal ulcer disease.

Keywords:
Acid secretion, Gastric cancer, Helicobacter pylori infection, Peptic ulcer disease
1.
Marshall BJ, Armstrong JA, McGechie DB, et al: Attempt to fulfill Koch’s postulates for pyloric Campylobacter. Med J Aust 1985;142:436–439.
2.
Morris A, Nicholson G: Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82:192–199.
3.
Sobala GM, Crabtree JE, Dixon MF, et al: Acute H. pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991;32:1415–1418.
4.
Ramsey EJ, Carey KV, Peterson WL, et al: Epidemic gastritis with hypochlorhydria. Gastroenterology 1979;76:1449–1457.
5.
Peterson W, Lee E, Skoglund M: The role of Campylobacter pyloridis in epidemic gastritis with hypochlorhydria. Gastroenterology 1987;92:1575.
6.
Graham DY, Alpert LC, Smith JL, et al: Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. Am J Gastroenterol 1988;83:974–980.
7.
Dixon MF, Genta JH, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181.
8.
Lee A, Dixon MF, Danon SJ, et al: Local acid production and H. pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 1995;7:461–465.
9.
Malfertheiner P, Chan FK, McColl KE: Peptic ulcer disease. Lancet 2009;374:1449–1461.
10.
Malagelada JR, Longstreth GF, Deering TB, Summerskill WH, Go VL: Gastric secretion and emptying after ordinary meals in duodenal ulcer. Gastroenterology 1977;73:989–993.
11.
Gillen D, El-Omar EM, Wirz AA, Ardill JE, McColl KE: The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 1998;114:50–57.
12.
Calam J, Levi S, Beardshall K, Playford R, Ghosh P, Swift I, Foulkes W, Haddad G: Helicobacter pylori and duodenal ulcer – the gastrin link; in Malfertheiner P, Ditschuneit H (eds): Helicobacter pylori, Gastritis and Peptic Ulcer. Berlin, Springer, 1990, pp 317–326.
13.
Moss SF, Legon S, Bishop AE, et al: Effect of H. pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992;340:930–932.
14.
Odum I, Petersen HD, Andersen IB, Hansen BF, Rehfeld JF: Gastrin and somatostatin in H. pylori-infected antral mucosa. Gut 1994;35:615–618.
15.
Levi S, Beardshall K, Haddad G, et al: Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1989;1:1167–1168.
16.
Olbe L, Hamlet A, Dalenbäck J, Fändriks L: A mechanism by which H. pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 1996;110:1386–1394.
17.
Hamlet A, Olbe L: The influence of H. pylori infection on postprandial duodenal acid load and duodenal bulb pH in humans. Gastroenterology 1996;111:391–400.
18.
El-Omar E, Penman I, Dorrian CA, et al: Eradicating H. pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993;34:1060–1065.
19.
McColl KEL, Fullarton GM, el Nujumi AM, et al: Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer. Lancet 1989;ii:499–500.
20.
McColl KEL, Gillen D, El-Omar E: The role of gastrin in ulcer pathogenesis; in Tytgat GNJ (ed): Baillière’s Best Practice and Research. Clinical Gastroenterology and Peptic Ulcer Disease. London, Harcourt, 2000.
21.
Malfertheiner P, Stanescu A, Bode G, Baczako K, Kühl P, Ditschuneit H: Gastric metaplasia in duodenal mucosa – key factor for H. pylori colonization and duodenal ulcer pathogenesis?; in Malfertheiner P, Ditschuneit H (eds): Helicobacter pylori, Gastritis and Peptic Ulcer. Berlin, Springer, 1990, pp 292–301.
22.
Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ: Clinical and pathological importance of heterogenicity in vacA, the vacuolating cytotoxin gene of H. pylori. Gastroenterology 1997;112:92–99.
23.
Lu H, Hsu PI, Graham DY, Yamaoka Y: Duodenal ulcer-promoting gene of H. pylori. Gastroenterology 2005;128:833–848.
24.
Hussein NR, Argent RH, Marx CK, Patel SR, Robinson K, Atherton JC: H. pylori dupA is polymorphic, and its active form induces proinflammatory cytokine secretion by mononuclear cells. J Infect Dis 2010;202:261–269.
25.
Wolfe MM, Nompleggi DJ: Cytokine inhibition of gastric acid secretion – a little goes a long way. Gastroenterology 1992;102:2177–2178.
26.
Beales IL, Calam J: Interleukin-1β and tumour necrosis factor-α inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 1998;42:227–234.
27.
El-Omar EM, Penman ID, Ardill JE, et al: H. pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109:681–691.
28.
Saha A, Hammond CE, Beeson C, Peek RM Jr, Smolka AJ: H. pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa. Gut 2010;59:874–881.
29.
Amedei A, Bergman MP, Appelmelk BJ, et al: Molecular mimicry between H. pylori antigens and H+,K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003;198:1147–1156.
30.
Bergman MP, Vandenbroucke-Grauls CM, Appelmelk BJ, et al: The story so far: H. pylori and gastric autoimmunity. Int Rev Immunol 2005;24:63–91.
31.
Verdu EF, Armstrong D, Idström JP, et al: Intragastric pH during treatment with omeprazole: role of H. pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996;31:1151–1156.
32.
Labenz J, Tillenburg B, Peitz U, et al: Efficacy of omeprazole one year after cure of H. pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576–581.
33.
Holtmann G, Cain C, Malfertheiner P: H. pylori accelerates healing of reflux oesophagitis during the treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11–16.
34.
Malfertheiner P, Megraud F, O’Morain C, et al: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–781.
35.
Kuipers EJ, Lundell L, Klinkenberg EC, et al: Atrophic gastritis and H. pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018–1022.
36.
Stolte M, Bethke B: Elimination of H. pylori under treatment with omeprazole. Z Gastroenterol 1990;28:271–274.
37.
Klinkenberg-Knol EC, Nelis F, Dent J, et al: Long-term omeprazole treatment in resistant esophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661–669.
38.
Horii T, Koike T, Abe Y, et al: Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan: evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol 2011;46:710–719.
39.
Ohata H, Kitauchi S, Yoshimura N, et al: Progression of chronic atrophic gastritis associated with H. pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138–143.
40.
Varis K, Sipponen P, Laxen F, et al: Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 2000;35:950–956.
41.
Miki K, Fujishiro M, Kodashima S, Yahagi N: Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009;21:78–81.
42.
Leung WK, Wu MS, Kakugawa Y, et al: Screening of gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008;9:279–287.
43.
Agreus L, Kuipers E, Kupcinskas L, et al: Diagnosis of atrophic gastritis with plasma biomarkers. A review article. Scand J Gastroenterol (accepted 2011).
44.
Kikuchi R, Abe Y, Iijima K, et al: Low serum levels of pepsinogen and gastrin-17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med 2011;223:35–44.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.